Randomized Trialhigh evidence
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
The New England journal of medicine·November 6, 2025·PMID 40960239
Why it mattersOrforglipron is a nonpeptide oral GLP-1 agonist, offering a potential alternative to injectable agents for obesity management. Its efficacy and safety profile in a large phase 3 trial support its role in expanding treatment options, particularly for patients averse to injections.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled